Dabuzalgron

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM.

Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM. ERK1 / 2 activation helps Dabuzaron's cardioprotection. Dabuzaron (10 μM; 4 hours) protects NRVM from cell death caused by doxorubicin (DOX). Dabuzaren (10 μM; 4 hours) activation of α1A-AR alleviates the harmful effects of DOX on mitochondrial membrane potential and eliminates the activation of important elements of the apoptotic response to mitochondrial damage.Dabuzaron (10μg / kg; oral tube; twice daily; 7 consecutive days; C57B16J wild-type or α1A-AR gene knockout mice) treatment can prevent DOX cardiotoxicity by activating α1A-AR. Dabuzaron prevents mitochondrial function-related transcript reduction, up-regulates PGC1α, retains ATP content, and reduces oxidative stress in DOX-treated mouse hearts.

Ro 115-1240

Angiogenesis

Adrenergic Receptor

α1A-adrenergic receptor

——

——

219311-44-1

317.79

C12H16ClN3O3S

>98% (HPLC)

DMSO:25 mg/mL(78.67 mM)

Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years